共 18 条
Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral Infection
被引:158
作者:
Li, Qingsheng
[1
]
Skinner, Pamela J.
[2
]
Ha, Sang-Jun
[3
]
Duan, Lijie
[1
]
Mattila, Teresa L.
[2
]
Hage, Aaron
[2
]
White, Cara
[2
]
Barber, Daniel L.
[4
]
O'Mara, Leigh
[3
]
Southern, Peter J.
[1
]
Reilly, Cavan S.
[5
]
Carlis, John V.
[6
]
Miller, Christopher J.
[7
]
Ahmed, Rafi
[3
]
Haase, Ashley T.
[1
]
机构:
[1] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA
[3] Emory Univ, Sch Med, Emory Vaccine Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[4] NIAID, Immunobiol Sect, Bethesda, MD 20892 USA
[5] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Inst Technol, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA
[7] Univ Calif Davis, Calif Natl Primate Res Ctr, Ctr Comparat Med, Davis, CA 95616 USA
来源:
关键词:
LYMPHOCYTIC CHORIOMENINGITIS VIRUS;
SIMIAN IMMUNODEFICIENCY VIRUS;
CD8(+) T-CELLS;
SIV INFECTION;
PERSISTENCE;
TRANSMISSION;
GLYCOPROTEIN;
REPLICATION;
RESPONSES;
EPITOPES;
D O I:
10.1126/science.1168676
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
In the early stages of viral infection, outcomes depend on a race between expansion of infection and the immune response generated to contain it. We combined in situ tetramer staining with in situ hybridization to visualize, map, and quantify relationships between immune effector cells and their targets in tissues. In simian immunodeficiency virus infections in macaques and lymphocytic choriomeningitis virus infections in mice, the magnitude and timing of the establishment of an excess of effector cells versus targets were found to correlate with the extent of control and the infection outcome (i.e., control and clearance versus partial or poor control and persistent infection). This method highlights the importance of the location, timing, and magnitude of the immune response needed for a vaccine to be effective against agents of persistent infection, such as HIV-1.
引用
收藏
页码:1726 / 1729
页数:4
相关论文